Clinical trials: Otorhinolaryngologic Neoplasms
Quality of Life, Cancer
Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
This project aims to explore, in depth, the burden of hearing loss and tinnitus on cancer survivors. Using semi-structured interviews, audiograms and a variety of validated questionnaires, the specific impact ototoxicity has on…
- Conditions
- Quality of Life, Cancer, Hearing Loss, Sensorineural, Tinnitus, Subjective
- Trial name
- NCT04281953
- Testing
- High frequency audiometry, Short-Form 36-Item Questionnaire (SF-36), Hearing handicap inventory for adults/elderly (HHIA/HHIE)
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Squamous Cell Carcinoma, Laryngeal Cancer
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
The purpose of this prospective, multi-institutional, observational cohort study is to determine if an initial surgical approach leads to better function and quality of life than primary chemoradiation in a subset of patients…
- Trial name
- NCT01089803
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- University of Minnesota
Esophageal Neoplasm, Anastomotic Leak
Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation
Analyze the correlation between the conformity of the anatomy (based on endoscopic examination) and postoperative anastomotic fistula and anastomotic stenosis; establish an anastomotic classification; and construct a predictive…
- Conditions
- Esophageal Neoplasm, Anastomotic Leak, Recurrent Laryngeal Nerve Injuries, Anastomotic Stenosis
- Trial name
- NCT06348381
- Testing
- No intervention
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer, Kidney Cancer
GI Organ Tracking Via Balloon Applicators
The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.
- Conditions
- Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer
- Trial name
- NCT05471401
- Testing
- Balloon-tipped catheter
- Sponsor
- Washington University School of Medicine
Neurofibromatosis 1, Neurofibromatosis 2
The NF Registry Sponsored by the Children's Tumor Foundation
The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to…
- Conditions
- Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
- Trial name
- NCT01885767
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- The Children's Tumor Foundation
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Head and Neck Cancer
Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy
Background: Dysphagia is a common side effect after radiotherapy for haed and neck cancer patients. It may be worsened by immobility of the throat during tube feeding. Hypothesis: Exercises may prevent or reduce late dysphagia.
- Trial name
- NCT00332865
- Testing
- Swallowing Exercises
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.
- Trial name
- NCT04978012
- Testing
- Fluzoparib and Camrelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06323460
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the drug's toxicity is manageable.
- Trial name
- NCT01392235
- Testing
- Famitinib
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.
- Trial name
- NCT05912582
- Testing
- Intensity modulated radiation therapy (IMRT) combined with chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma, T2-3N0 or T1-2N1
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
To evaluate the safety and efficacy of PD-1 immune checkpoint inhibitor combined with intensity modulated radiation therapy in the treatment of intermediate-risk nasopharyngeal carcinoma (T2-3N0 or T1-2N1 stage and EBV-DNA≤4000…
- Conditions
- Nasopharyngeal Carcinoma, T2-3N0 or T1-2N1, EBV-DNA≤4000 Copy/ml
- Trial name
- NCT05229315
- Testing
- Toripalimab, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- XIANG YANQUN
Nasopharyngeal Carcinoma
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
The goal of this clinical trial is to compare the efficacy and safety of curative radiotherapy with or without induction chemotherapy in patients with T3N1M0 nasopharyngeal carcinoma.
- Trial name
- NCT05622474
- Testing
- Induction chemotherapy plus Concurrent chemotherapy, Concurrent chemotherapy, IMRT
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma.
- Trial name
- NCT06611150
- Testing
- Nab-paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Oropharyngeal Carcinoma (OPC)
HPV-associated Oropharyngeal Carcinoma (HPV-OPC)
This study focuses on the longitudinal monitoring of HPV infection in patients with head and neck cancers, particularly oropharyngeal carcinoma (OPC), using a new electrochemical detection method.
- Trial name
- HPV-OPC (NCT07718620)
- Testing
- HPV p16, HPV testing - positive results, HPV testing - negative results
- Where
- Czechia
- Volunteers
- 35 people
- Sponsor
- Masaryk Memorial Cancer Institute
Nasopharyngeal Neoplasms
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
In an effort to identify genetic factors linked to the development of nasopharyngeal cancer (NPC), the researchers identified and sampled 2,394 individuals from Taiwanese families in which two or more relatives had been diagnosed…
- Trial name
- NCT00393224
- Where
- China
- Volunteers
- 952 people
- Sponsor
- National Cancer Institute (NCI)
Hypopharyngeal Carcinoma
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
This is a multi-center, randomized controlled, prospective clinical study.
- Trial name
- NCT07248956
- Testing
- Finolizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Cisplatin
- Where
- 7 sites in China
- Volunteers
- 116 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.
- Trial name
- NCT02328261
- Testing
- Icotinib
- Volunteers
- 66 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Cancer, Solid Malignant Tumors
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature…
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC
- Trial name
- NCT06915454
- Testing
- Intra-op PET/CT Specimen Scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.